Drug Trial Radar · NCT07524101
Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,952
Planned (sponsor's estimate)
Start
May 28, 2026
Primary completion
Jan 22, 2031
Study completion Jan 22, 2031
Sponsor
- Lead sponsor
- Yonsei UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The ULTRA-CKD trial is a prospective, randomized, open-label, multicenter trial designed to compare the efficacy and safety of moderate-intensity statin plus ezetimibe combination therapy versus high-intensity statin monotherapy in patients with chronic kidney disease (CKD) and concomitant atherosclerotic cardiovascular disease (ASCVD). Patients with CKD are at very high risk for ASCVD. In this population, it is important to establish a lipid-lowering strategy that optimizes cardiovascular outcomes while ensuring long-term safety. While high-intensity statins are generally considered as initial treatment option for secondary prevention, the optimal strategy for CKD patients remains to be clinicaly defined. This study aims to evaluate whether the combination of moderate-intensity statin and ezetimibe is non-inferior to high-intensity statin monotherapy in terms of 3-year composite of major adverse cardiovascular events.
Conditions
- Renal Insufficiency
- Atherosclerosis
- Dyslipidemia
- Hypercholesterolemia
- Cardiovascular Diseases
Interventions
Moderate-intensity statin and ezetimibe combination therapyDrug
Participants will receive moderate-intensity statin plus ezetimibe (pitavastatin 1-4 mg + ezetimibe 10 mg once daily or atorvastatin 10-20 mg + ezetimibe 10 mg once daily), with 36-month follow-up.
High-intensity statin monotherapyDrug
Participants will receive high-intensity statin monotherapy (atorvastatin 40 mg once daily), with 36-month follow-up.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major adverse cardiovascular eventsTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.